31 October 2019
Sixty-one percent of foreign companies have seen an improvement in Russia’s business climate in the past year, the U.S.-Russia Business Council reported, citing a new Russian-language report by EY.
The number of positive reviews is the largest among Asian companies (78%), followed by U.S. and EU companies (64% and 49%, respectively).
Eighty-five percent of the foreign firms surveyed expect “slow expansion” of their business in Russia in the next three years. Growth expectations are the highest among healthcare and pharmaceutical companies (44%), followed by construction (40%) and energy (36%) firms. Most companies link growth expectations to new product launches and 40% to higher production volumes.
Half of the companies plan to expand their operations to Russia’s central and northwestern regions. In choosing new investment destinations, Asian firms prioritize local tax benefits while U.S. companies value opportunities for direct dialog with local authorities and the availability of skilled workers.
Forty-one percent of Asian companies plan to increase investment in Russia this year, as do 29% of U.S. or EU firms. In 2019, the total volume of new investment by the companies surveyed is estimated at $6.5bn, of which 44% would go to the energy and extractive sectors.
Although most companies included in the report (62%) noted adverse effects of sanctions on their businesses, 58% suffered only “modest” revenue losses due to sanctions. Among the negative effects of sanctions, 44% pointed to an overall contraction of the Russian market, 27% cited limited access to financing, 25% complained about supply chain disruptions, and 24% were concerned about reputational risks. Only 8% of foreign firms had to shut down existing projects and 7% had to cancel prospective projects in Russia due to sanctions.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024